2. Cell Cycle/DNA Damage Epigenetics NF-κB JAK/STAT Signaling Stem Cell/Wnt Metabolic Enzyme/Protease
  3. Sirtuin NF-κB STAT Angiotensin-converting Enzyme (ACE)
  4. Perindopril erbumine

Perindopril erbumine  (Synonyms: Perindopril tert-butylamine salt; S-9490 erbumine)

Cat. No.: HY-B0130A Purity: 99.98%
COA Handling Instructions

Molarity Calculator

Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.

For research use only. We do not sell to patients.

Perindopril erbumine Chemical Structure

Perindopril erbumine Chemical Structure

CAS No. : 107133-36-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 57 In-stock
Solution
10 mM * 1 mL in DMSO USD 57 In-stock
Solid
100 mg USD 52 In-stock
250 mg USD 89 In-stock
500 mg USD 128 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Perindopril erbumine:

Perindopril erbumine Related Antibodies

Top Publications Citing Use of Products

View All Sirtuin Isoform Specific Products:

View All Isoforms
Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure[1][2][3][4].

IC50 & Target

SIRT3

 

STAT3

 

In Vitro

Perindopril erbumine (1 μM, 24 h) ameliorats gliosis and blunts decrease induced by LPS (HY-D1056) in AT2R expression in Rat astrocytoma cell line (C6) and murine microglial cell line (BV2)[1].
Perindopril erbumine (1 μM, 24 h) prevents IκBα degradation, NF-кB nuclear translocation and STAT3 activation induced by LPS (HY-D1056) in C6 and BV2[1].
Perindopril erbumine (1 μM, 24 h) ameliorats the imbalance in the release of inflammatory cytokine and blunts the aberrant ROS production and the nitrite release induced by LPS (HY-D1056) in C6 and BV2[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Perindopril erbumine Related Antibodies
In Vivo

Perindopril erbumine (0.1 mg/kg, Oral gavage, once a day for five consecutive days) prevents LPS-induced neuroinflammation in rats[1].
Perindopril erbumine (0.42 mg/kg, Oral, once a day for 4 weeks) with Huangqi-Danshen decoction (HDD) (4.7 g/kg, Oral, once a day for 4 weeks) attenuates adenine(HY-B0152)-induced Chronic kidney disease (CKD) in rats[2].
Perindopril erbumine (0.4-1.5 mg/kg, Oral, once a day for 4-24 weeks) has a persistent effect on blood pressure in spontaneously hypertensive rats (SHR)[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adenine-induced chronic kidney disease rats[2]
Dosage: 0.1 mg/kg
Administration: Oral gavage (p.o.)
Result: Abolished the LPS-induced astroglial and microglial activation.
Attenuated LPS-induced TNF-α production.
Prevented LPS-induced nuclear translocation of NF-кB.
Prevented the AT1R up-regulation and the LPS-induced decrease in the expression of PP2A.
Animal Model: Chronic kidney disease rats[2]
Dosage: 0.42 mg/kg
Administration: Oral
Result: Obviously reduced serum creatinine (Scr) and blood urea nitrogen (BUN) levels.
Displayed a marked reduction of tubulointerstitial fibrosis.
Exhibited more inhibitory effect on Col-IV expression and a exceed effect of raising OPA-1 expression.
Significantly increased Sirtuin3 expression.
Prevented mitochondrial fragmentation.
Clinical Trial
Molecular Weight

441.60

Formula

C23H43N3O5
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC)C)=O)[C@@]2([H])CCCC[C@@]2([H])C1)O.CC(C)(C)N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : ≥ 50 mg/mL (113.22 mM)

DMSO : 10 mg/mL (22.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2645 mL 11.3225 mL 22.6449 mL
5 mM 0.4529 mL 2.2645 mL 4.5290 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (226.45 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.98%

COA (251 KB) RP-HPLC (206 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO / H2O 1 mM 2.2645 mL 11.3225 mL 22.6449 mL 56.6123 mL
5 mM 0.4529 mL 2.2645 mL 4.5290 mL 11.3225 mL
10 mM 0.2264 mL 1.1322 mL 2.2645 mL 5.6612 mL
15 mM 0.1510 mL 0.7548 mL 1.5097 mL 3.7742 mL
20 mM 0.1132 mL 0.5661 mL 1.1322 mL 2.8306 mL
H2O 25 mM 0.0906 mL 0.4529 mL 0.9058 mL 2.2645 mL
30 mM 0.0755 mL 0.3774 mL 0.7548 mL 1.8871 mL
40 mM 0.0566 mL 0.2831 mL 0.5661 mL 1.4153 mL
50 mM 0.0453 mL 0.2264 mL 0.4529 mL 1.1322 mL
60 mM 0.0377 mL 0.1887 mL 0.3774 mL 0.9435 mL
80 mM 0.0283 mL 0.1415 mL 0.2831 mL 0.7077 mL
100 mM 0.0226 mL 0.1132 mL 0.2264 mL 0.5661 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Perindopril erbumine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Perindopril107133-36-8Perindopril tert-butylamineS-9490S9490S 9490SirtuinNF-κBSTATAngiotensin-converting Enzyme (ACE)Nuclear factor-κBNuclear factor-kappaBRat astrocytoma cell line (C6)murine microglial cell line (BV2)Chronic kidney diseaseNeuroinflammationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Perindopril erbumine
Cat. No.:
HY-B0130A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.